Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Growth in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 78,500 shares, an increase of 102.8% from the January 31st total of 38,700 shares. Based on an average daily volume of 25,400 shares, the days-to-cover ratio is presently 3.1 days. Currently, 0.7% of the shares of the stock are sold short.

Indaptus Therapeutics Price Performance

INDP stock traded down $0.03 on Monday, hitting $0.81. 3,111 shares of the company were exchanged, compared to its average volume of 23,675. The stock has a market capitalization of $11.37 million, a price-to-earnings ratio of -0.47 and a beta of 1.46. The business’s fifty day moving average is $0.87 and its two-hundred day moving average is $1.13. Indaptus Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.10.

Analyst Ratings Changes

Separately, Maxim Group reduced their target price on shares of Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.